Telix Opens First APAC Radiopharmaceutical Manufacturing Site in Japan
Telix Pharmaceuticals has officially opened its first cyclotron-equipped manufacturing facility in the Asia-Pacific region, marking a significant expansion of the company’s radiopharmaceutical production capabilities. The new site, known as Telix Manufacturing Solutions (TMS) Yokohama, is located in Yokohama, Japan, and represents an important milestone in the company’s regional clinical and commercial strategy.
The Yokohama facility is expected to strengthen access to advanced radiopharmaceuticals for patients across Japan. Initially, the site will support clinical supply of TLX250-CDx, Telix’s investigational imaging agent designed for kidney cancer detection. TLX250-CDx uses antibody-based targeting to identify clear cell renal cell carcinoma, the most common form of kidney cancer, and has shown significant potential in improving diagnostic accuracy.
Beyond TLX250-CDx, Telix plans to leverage the facility to supply additional investigational and future commercial products, pending regulatory approvals. These include radiopharmaceuticals aimed at prostate and brain cancer, expanding the company’s precision imaging and therapeutic portfolio. By housing a cyclotron on-site—a technology essential for producing short-lived radioisotopes—TMS Yokohama will enable faster, more reliable distribution of radiopharmaceuticals to hospitals and clinical sites throughout Japan.
To commemorate the facility’s grand opening, Telix hosted a special lecture delivered by Professor Jun Hatazawa, Vice President of the Japan Isotope Association and a leading academic at Osaka University’s Next-Generation Cancer Therapy Research Division. His address, titled “Trends and Challenges for the Future of Nuclear Medicine,” highlighted the increasing importance of radiopharmaceutical innovation and emphasized the role of domestic manufacturing in advancing patient care and research.
Raphael Ortiz, CEO International Business and Japan President at Telix, underscored the significance of the Yokohama expansion for the company and for the broader nuclear medicine landscape in Asia Pacific. “The opening of TMS Yokohama is a significant milestone for Telix as it enhances our capacity to meet growing demand for radiopharmaceuticals in Japan and Asia Pacific,” Ortiz said. He noted that Japan, as the world’s second-largest nuclear medicine market, continues to be integral to Telix’s clinical development and commercial objectives.
Ortiz added that the launch of the Yokohama facility reaffirms the company’s long-term commitment to Japanese patients, scientific collaboration, and the advancement of nuclear medicine. The new infrastructure positions Telix to accelerate clinical programs while preparing for future commercial launches, ultimately aiming to bring more effective diagnostic and therapeutic options to cancer patients throughout the region.
With TMS Yokohama now operational, Telix steps into a new phase of regional growth, enhancing both local manufacturing capabilities and access to next-generation radiopharmaceuticals.